(COGT) Cogent Biosciences - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.584m USD | Total Return: 560% in 12m
Avg Turnover: 51.9M
Warnings
Interest Coverage Ratio -84.7 is critical
Altman Z'' -7.36 < 1.0 - financial distress zone
Fakeout Below Avwap Earnings
Tailwinds
Leader
Cogent Biosciences, Inc. is a clinical-stage biotechnology firm specializing in precision therapies for genetically defined diseases. Its primary asset, bezuclastinib, is a selective tyrosine kinase inhibitor currently in Phase 3 trials targeting KIT receptor mutations associated with systemic mastocytosis and gastrointestinal stromal tumors. The companys pipeline also includes early-stage inhibitors for FGFR2, ErbB2, and PI3Ka mutations, addressing various solid tumors and central nervous system indications.
The clinical-stage biotechnology sector typically requires significant research and development expenditure before achieving commercial revenue, often relying on successful Phase 3 outcomes for regulatory approval. Cogent utilizes a targeted kinase inhibition model, which aims to improve efficacy and reduce off-target toxicity compared to broad-spectrum treatments. For deeper insights into these clinical milestones, ValueRay provides comprehensive data for further investigation. Headquartered in Waltham, Massachusetts, the company maintains a strategic licensing agreement with Plexxikon Inc. for its lead candidates development.
- Bezuclastinib Phase 3 clinical trial results for Systemic Mastocytosis determine valuation
- Regulatory approval timeline for KIT D816V mutation therapies impacts market entry
- Competition in the gastrointestinal stromal tumor space pressures future market share
- Research and development expenses for early-stage pipeline accelerate cash burn rates
- Licensing agreement obligations to Plexxikon influence long-term net profit margins
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.33 > 0.02 and ΔFCF/TA 46.52 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.32 > 3% & CFO -284.8m > Net Income -354.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.4m) vs 12m ago -40.50% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.51%; Δ -1.51% > 0%) |
| Interest Coverage Ratio: -84.69 > 6 (EBITDA TTM -362.0m / Interest Expense TTM 4.28m) |
| A: 0.91 (Total Current Assets 877.8m - Total Current Liabilities 58.0m) / Total Assets 903.0m |
| B: -1.42 (Retained Earnings -1.29b / Total Assets 903.0m) |
| C: -0.61 (EBIT TTM -362.0m / Avg Total Assets 593.4m) |
| D: -4.35 (Book Value of Equity -1.29b / Total Liabilities 295.3m) |
| Altman-Z'' = -7.36 = D |
As of May 24, 2026, the stock is trading at USD 32.58 with a total of 1,576,744 shares traded.
Over the past week, the price has changed by -0.03%,
over one month by -10.22%,
over three months by -11.85% and
over the past year by +560.00%.
Cogent Biosciences has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy COGT.
- StrongBuy: 5
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 54.3 | 66.5% |
P/B = 10.933
Revenue TTM = 0.0 USD
EBIT TTM = -362.0m USD
EBITDA TTM = -362.0m USD
Long Term Debt = 222.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.38m USD (from shortTermDebt, last quarter)
Debt = 254.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.9m
Net Debt = -591.8m USD (calculated: Debt 254.6m - CCE 846.3m)
Enterprise Value = 4.99b USD (5.58b + Debt 254.6m - CCE 846.3m)
Interest Coverage Ratio = -84.69 (Ebit TTM -362.0m / Interest Expense TTM 4.28m)
EV/FCF = -16.74x (Enterprise Value 4.99b / FCF TTM -298.1m)
FCF Yield = -5.97% (FCF TTM -298.1m / Enterprise Value 4.99b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 4.62m) / Revenue TTM)
Tobins Q-Ratio = 5.53 (Enterprise Value 4.99b / Total Assets 903.0m)
Interest Expense / Debt = 1.68% (Interest Expense 4.28m / Debt 254.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -286.0m (EBIT -362.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.24 (Total Current Assets 877.8m / Total Current Liabilities 71.7m)
Debt / Equity = 0.42 (Debt 254.6m / totalStockholderEquity, last quarter 607.7m)
Debt / EBITDA = 1.63 (negative EBITDA) (Net Debt -591.8m / EBITDA -362.0m)
Debt / FCF = 1.98 (negative FCF - burning cash) (Net Debt -591.8m / FCF TTM -298.1m)
Total Stockholder Equity = 425.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.71% (Net Income -354.3m / Total Assets 903.0m)
RoE = -20.71% (Net Income TTM -354.3m / Total Stockholder Equity 1.71b)
RoCE = -18.72% (EBIT -362.0m / Capital Employed (Equity 1.71b + L.T.Debt 222.9m))
RoIC = -37.80% (negative operating profit) (NOPAT -286.0m / Invested Capital 756.7m)
WACC = 11.61% (E(5.58b)/V(5.84b) * Re(12.08%) + D(254.6m)/V(5.84b) * Rd(1.68%) * (1-Tc(0.21)))
Discount Rate = 12.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.47 | Cagr: -10.59%
[DCF] Fair Price = unknown (Cash Flow -298.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.09 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.57 | Chg30d=-4.17% | Revisions=-20% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.57 | Chg30d=-1.57% | Revisions=-20% | Analysts=9
EPS current Year (2026-12-31): EPS=-2.26 | Chg30d=-5.10% | Revisions=-45% | GrowthEPS=-6.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.94 | Chg30d=-36.51% | Revisions=-11% | GrowthEPS=+58.4% | GrowthRev=+3318.6%
[Analyst] Revisions Ratio: -45%